<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829372</url>
  </required_header>
  <id_info>
    <org_study_id>GBR 1302-101</org_study_id>
    <secondary_id>2015-002926-38</secondary_id>
    <nct_id>NCT02829372</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers</brief_title>
  <acronym>GBR 1302-101</acronym>
  <official_title>A Phase 1, First-in-man, Multicenter, Open-label, Dose-escalation Study of Single-agent GBR 1302 in Subjects With HER2 Positive Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Pharmaceuticals S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glenmark Pharmaceuticals S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD)
      of GBR 1302 monotherapy in subjects with HER2 positive cancers
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Tolerated Dose (MTD) of GBR 1302</measure>
    <time_frame>28 Days</time_frame>
    <description>Number of DLTs (dose limiting toxicities) after the first two administrations of study drug (i.e. Cycle 1) in each cohort</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The relationship of the dose of GBR 1302 with the incidence, nature, and intensity of AEs according to CTCAEv4.03</measure>
    <time_frame>28 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) for solid tumors.</measure>
    <time_frame>2 cycles, 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) for solid tumors</measure>
    <time_frame>2 cycles, 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of disease control (measured from drug start date to the date of disease progression or death for subjects who had CR or PR or SD during treatment).</measure>
    <time_frame>At least 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of GBR 1302</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of GBR 1302</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve [AUC0-t and AUC0-tau] of GBR 1302</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of GBR 1302 in terms of ADA formation assessed compared to baseline</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HER2 Expressing Solid Tumours</condition>
  <arm_group>
    <arm_group_label>GBR 1302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD3/HER2 bispecific monoclonal antibody</intervention_name>
    <description>Increasing doses, IV on day 1 and 15 of each 28 day cycle</description>
    <arm_group_label>GBR 1302</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Progressive HER2 positive solid tumours (immunohistochemistry [IHC] positive or
             equivocal) with no available standard or curative treatment.

          2. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.

        Exclusion Criteria:

          1. Active infectious disease considered by the Investigator to be incompatible with the
             protocol.

          2. Patients not recovered from any therapy-related toxicities from previous therapies to
             at least CTCAE â‰¤ Grade 1 except in case of liver metastases or Gilbert's Syndrome or
             alopecia.

          3. Brain metastases that are symptomatic or untreated or that require current therapy.

          4. Previous treatment with immunotherapy within 8 weeks of starting study medication,
             chemotherapy, radiotherapy, molecular-targeted therapy, or biological therapies
             (including HER2 directed therapies) within 4 weeks of starting study medication, or
             hormone therapy within 2 weeks of starting study medication.

          5. Use of any investigational drug within the past 4 weeks before start of study
             medication or concomitantly with this study except for investigational
             immune-stimulatory therapy (e.g. checkpoint-regulator targeted treatment). The minimum
             washout period should be 8 weeks before starting the study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eliel Bayever, MBBCh, MRCP</last_name>
    <role>Study Director</role>
    <affiliation>Glenmark Pharmaceutical S.A</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Phumla Adesanya</last_name>
    <phone>(201) 684-8000</phone>
    <email>clinicaltrialsdisclosuredesk@glenmarkpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Glenmark Investigational Site 204</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qamar Khan, MD</last_name>
      <phone>913-558-6029</phone>
      <email>qkhan@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 209</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Weise, DO</last_name>
      <phone>313-576-8624</phone>
      <email>weisea@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 201</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Mrinal Barve, MD</last_name>
      <email>mbarve@marycrowley.org</email>
    </contact>
    <contact_backup>
      <phone>+1 214 793 6132</phone>
      <email>referral@marycrowley.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 203</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Garrido-Laguna, MD, Ph.D</last_name>
      <phone>801-587-4700</phone>
      <email>Ignacio.Garrido-Laguna@hci.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 103</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Sebastian Ochsenreither, MD</last_name>
      <phone>+49 30 450 564 621</phone>
      <email>sebastian.ochsenreither@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 102</name>
      <address>
        <city>Cologne</city>
        <zip>50670</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 101</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Martin Wermke, MD</last_name>
      <phone>+49 351 458-4695</phone>
      <email>martin.wermke@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 104</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Hildegard Nolte, MD</last_name>
      <phone>+49 6131 17-5950</phone>
      <email>hildegard.nolte@unimedizin-mainz.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2016</study_first_submitted>
  <study_first_submitted_qc>July 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

